This is a significantly confounded trial. Any treated patient that showed pseudo-progression or actual progression were then given another DCVax-L dose. So many of the trial patients received more than the single dose the trial was designed to measure. That is confounding the OS data and favoring the treatment arm when the external comparator trials used well-controlled dosing.
Dr. Liau was confirming the PFS primary endpoint 12 years after the trial was started in here 2018 journal publication. It was only AFTER the trial ended and was unblinded that all the endpoints were redone. And they naïve OS data is still confounded. NWBO specifically said so in their SEC filings. Therefore the data is questionable. I'd have FUD. It is well justified with this manipulated clinical trial.
Market Data 
Markets 
AI
